---
layout: default
title: Vemurafenib
parent: AI Predictions (L5)
nav_order: 662
evidence_level: L5
indication_count: 10
---

# Vemurafenib
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Vemurafenib: From BRAF-V600-Mutated Melanoma to HIV Infectious Disease

## One-Sentence Summary

Vemurafenib is a BRAF V600 kinase inhibitor, originally used as monotherapy for adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.
The TxGNN model predicts it may be effective for **HIV infectious disease**, but **no clinical trials and no publications** currently support this direction, so the prediction rests on the model alone.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | BRAF-V600-mutation-positive unresectable or metastatic melanoma (monotherapy, adults) |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 97.65% |
| Evidence Level | L5 |
| EU Market Status | Cancelled only |
| Number of Authorizations | 1 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Vemurafenib is known as an inhibitor of the mutated BRAF V600 kinase, and its efficacy in BRAF-mutated melanoma is the basis of its approval.

No mechanistic link between BRAF inhibition and HIV infection could be established from the available data. The prediction score is a computational output only, and no pathway-level rationale can be assessed. The same applies to the other high-ranking predictions (simian immunodeficiency virus infection and feline acquired immunodeficiency syndrome). These share a score and likely come from the same retroviral neighbourhood in the knowledge graph, so they should not be read as independent confirmation. The latter two are animal diseases with no direct human clinical relevance.

For context, the only predicted indication with any supporting literature is **female breast carcinoma** (rank 8, score 95.15%). It is rated L4 and framed as a research question rather than a recommendation. That evidence consists of case reports, reviews and melanoma-focused studies. One case report describes vemurafenib-induced progression of breast cancer, which suggests a paradoxical MAPK activation concern in BRAF-wild-type tumours. BRAF V600E mutations are rare in breast cancer, so any benefit would be limited to a small molecular subset.

## Clinical Trial Evidence

Currently no related clinical trials are registered for HIV infectious disease.

## Literature Evidence

Currently no related literature is available for HIV infectious disease.

## EU Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| EMEA/H/C/002409 (cancelled) | Zelboraf | Not specified | Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma. |

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (BRAF kinase inhibitor) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |

## Safety Considerations

Label-based warnings and contraindications are not available in the data compiled for this report. Please refer to the SmPC for safety information.

- **Contraindications flagged by the knowledge graph** (computational drug-disease contraindication edges, not label text): long QT syndrome, familial long QT syndrome, torsades de pointes, potassium deficiency disease, hypercalcemia disease, nephrocalcinosis, phosphorus metabolism disease, hyperbilirubinemia, hereditary hyperbilirubinemia, Gilbert syndrome, uveitis, iris disease, ciliary body disease, panuveitis and iritis. The literature also contains reports of uveitis during vemurafenib treatment.
- **Drug interactions**: 100 interactions were found in total, and the 20 shown here include 3 rated Major and 1 further Major-level pairing noted below.
  - Major: clarithromycin, dolasetron, palonosetron.
  - Moderate examples: famotidine, pioglitazone, alosetron, loperamide, aprepitant, dexamethasone, sitagliptin, saxagliptin, linagliptin, naltrexone.
  - The QT-related contraindication signals and the Major interactions with QT-active drugs (such as dolasetron and palonosetron) call for caution in any new use.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The HIV prediction has a high model score but no clinical trials, no literature and no identified mechanism, so the evidence level is L5. In addition, the only EU authorization is cancelled, which limits the practical route to market.

**To proceed, the following is needed:**
- Mechanism of action data (for example from DrugBank) to test whether any biological link to HIV exists
- Preclinical or in vitro studies of vemurafenib in HIV models
- The SmPC warnings and contraindications, to complete safety screening, with particular attention to QT prolongation, ocular toxicity and drug interactions
- Clarification of the cancelled EU authorization status and available dosage forms and routes
- If prioritizing a better-supported direction, a separate review of the breast carcinoma signal, restricted to BRAF V600-mutant tumours and weighed against the paradoxical-activation risk
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

